495 related articles for article (PubMed ID: 23826859)
1. In vitro and in vivo influence of penetration enhancers in the topical application of celecoxib.
Quiñones OG; Mata dos Santos HA; Kibwila DM; Leitão A; dos Santos Pyrrho A; Pádula Md; Rosas EC; Lara MG; Pierre MB
Drug Dev Ind Pharm; 2014 Sep; 40(9):1180-9. PubMed ID: 23826859
[TBL] [Abstract][Full Text] [Related]
2. In Vitro and In Vivo Evaluation of DMSO and Azone as Penetration Enhancers for Cutaneous Application of Celecoxib.
Senna TD; Mata Dos Santos HA; Kibwila DM; Leitao AC; Santos Pyrrho AD; de Padula M; Rosas EC; Padua TA; Lara MG; Riemma Pierre MB
Curr Drug Deliv; 2017; 14(7):992-1004. PubMed ID: 28124617
[TBL] [Abstract][Full Text] [Related]
3. Liquid Crystalline Systems Based on Glyceryl Monooleate and Penetration Enhancers for Skin Delivery of Celecoxib: Characterization, In Vitro Drug Release, and In Vivo Studies.
Dante MCL; Borgheti-Cardoso LN; Fantini MCA; Praça FSG; Medina WSG; Pierre MBR; Lara MG
J Pharm Sci; 2018 Mar; 107(3):870-878. PubMed ID: 29108729
[TBL] [Abstract][Full Text] [Related]
4. Copaiba oil enhances in vitro/in vivo cutaneous permeability and in vivo anti-inflammatory effect of celecoxib.
Quiñones OG; Hossy BH; Padua TA; Miguel NCO; Rosas EC; Ramos MFS; Pierre MBR
J Pharm Pharmacol; 2018 Jul; 70(7):964-975. PubMed ID: 29600536
[TBL] [Abstract][Full Text] [Related]
5. Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies.
Estracanholli EA; Praça FS; Cintra AB; Pierre MB; Lara MG
AAPS PharmSciTech; 2014 Dec; 15(6):1468-75. PubMed ID: 24980082
[TBL] [Abstract][Full Text] [Related]
6. Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion.
Subramanian N; Ghosal SK; Moulik SP
Drug Dev Ind Pharm; 2005 May; 31(4-5):405-16. PubMed ID: 16093206
[TBL] [Abstract][Full Text] [Related]
7. Topical glycerol monooleate/propylene glycol formulations enhance 5-aminolevulinic acid in vitro skin delivery and in vivo protophorphyrin IX accumulation in hairless mouse skin.
Steluti R; De Rosa FS; Collett J; Tedesco AC; Bentley MV
Eur J Pharm Biopharm; 2005 Aug; 60(3):439-44. PubMed ID: 15996585
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment with skin permeability enhancers: importance of duration and composition on the delivery of diclofenac sodium.
Maurya A; Murthy SN
J Pharm Sci; 2014 May; 103(5):1497-503. PubMed ID: 24644068
[TBL] [Abstract][Full Text] [Related]
9. Topical delivery of celecoxib using microemulsion.
Subramanian N; Ghosal SK; Moulik SP
Acta Pol Pharm; 2004; 61(5):335-41. PubMed ID: 15747689
[TBL] [Abstract][Full Text] [Related]
10. Copaiba Oil: Chemical Composition and Influence on In-vitro Cutaneous Permeability of Celecoxib.
Quinones OG; Abranches RP; Nakamura MJ; de Souza Ramos MF; Riemma Pierre MB
Curr Drug Deliv; 2018; 15(3):357-366. PubMed ID: 28847273
[TBL] [Abstract][Full Text] [Related]
11. Effect of non-phospholipid-based cationic and phospholipid-based anionic nanosized emulsions on skin retention and anti-inflammatory activity of celecoxib.
Tamilvanan S; Baskar R
Pharm Dev Technol; 2013; 18(4):761-71. PubMed ID: 23668371
[TBL] [Abstract][Full Text] [Related]
12. Tulsi oil as a potential penetration enhancer for celecoxib transdermal gel formulations.
Shamsher AA; Charoo NA; Rahman Z; Pillai KK; Kohli K
Pharm Dev Technol; 2014 Feb; 19(1):21-30. PubMed ID: 23281713
[TBL] [Abstract][Full Text] [Related]
13. A novel transdermal delivery system for the anti-inflammatory lumiracoxib: influence of oleic acid on in vitro percutaneous absorption and in vivo potential cutaneous irritation.
Moreira TS; de Sousa VP; Pierre MB
AAPS PharmSciTech; 2010 Jun; 11(2):621-9. PubMed ID: 20373151
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of transdermal patches of celecoxib.
Alam MI; Baboota S; Kohli K; Ali J; Ahuja A
PDA J Pharm Sci Technol; 2009; 63(5):429-37. PubMed ID: 20158049
[TBL] [Abstract][Full Text] [Related]
15. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib.
Baboota S; Shakeel F; Ahuja A; Ali J; Shafiq S
Acta Pharm; 2007 Sep; 57(3):315-32. PubMed ID: 17878111
[TBL] [Abstract][Full Text] [Related]
16. Improving the topical delivery of zinc phthalocyanine using oleic acid as a penetration enhancer: in vitro permeation and retention.
da Silva ER; de Freitas ZM; Gitirana Lde B; Ricci-Júnior E
Drug Dev Ind Pharm; 2011 May; 37(5):569-75. PubMed ID: 21128702
[TBL] [Abstract][Full Text] [Related]
17. In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.
Song WH; Yeom DW; Lee DH; Lee KM; Yoo HJ; Chae BR; Song SH; Choi YW
Arch Pharm Res; 2014 May; 37(5):626-35. PubMed ID: 23852645
[TBL] [Abstract][Full Text] [Related]
18. In vitro permeation of carvedilol through porcine skin: effect of vehicles and penetration enhancers.
Gannu R; Vishnu YV; Kishan V; Rao YM
PDA J Pharm Sci Technol; 2008; 62(4):256-63. PubMed ID: 19174954
[TBL] [Abstract][Full Text] [Related]
19. Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention.
Pinheiro VA; Serikaku D; Baby AR; Velasco MV; Kaneko TM; Consiglieri VO
Pharm Dev Technol; 2015 Mar; 20(2):197-203. PubMed ID: 24286179
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib.
Bragagni M; Mennini N; Maestrelli F; Cirri M; Mura P
Drug Deliv; 2012; 19(7):354-61. PubMed ID: 23043648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
